导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 4.06% | 1476/4773 |
| 近一周 | -1.10% | 1679/5465 |
| 近一月 | -5.47% | 3771/5421 |
| 近一季 | -14.30% | 4281/5231 |
| 近半年 | -5.07% | 2984/4920 |
| 近一年 | 7.74% | 1430/4394 |
| 近两年 | 128.11% | 378/2954 |
| 近三年 | 86.40% | 210/2253 |
| 成立以来 | 139.32% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
3.05% 811/4961 |
22.32% 1131/5312 |
- - |
- - |
| 2025 | 54.75% 348/4813 |
6.52% 619/3635 |
9.38% 289/4076 |
30.16% 1196/4524 |
2.04% 1096/4813 |
| 2024 | 16.46% 809/3463 |
-6.61% 2068/2808 |
-5.00% 1614/3014 |
23.08% 418/3129 |
6.64% 492/3463 |
| 2023 | -3.13% 629/2656 |
7.72% 528/2280 |
-1.28% 469/2385 |
-7.37% 1563/2515 |
-1.66% 356/2655 |
| 2022 | -26.78% 1432/2207 |
-16.12% 1104/1919 |
3.77% 1093/2016 |
-16.78% 1501/2113 |
1.08% 1393/2208 |
| 2021 | 30.63% 65/1822 |
-0.90% 405/1255 |
23.03% 120/1330 |
2.10% 442/1466 |
4.94% 309/1822 |
| 2020 | - - |
- - |
- - |
6.51% 832/1164 |
7.11% 729/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 景顺长城创业板综指增强A VS. 长安沪深300非周期A(740101) |